Categories: Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Encephalitis

MalaCards integrated aliases for Encephalitis:

Name: Encephalitis 12 75 54 59 29 55 6 43 44 15 72


Orphanet: 59  
Rare neurological diseases

External Ids:

Disease Ontology 12 DOID:9588
MeSH 44 D004660
NCIt 50 C26760
SNOMED-CT 68 45170000
MESH via Orphanet 45 D004660
UMLS via Orphanet 73 C0014038
Orphanet 59 ORPHA97275
UMLS 72 C0014038

Summaries for Encephalitis

NINDS : 54 Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get encephalitis or meningitis. Causes of encephalitis and meningitis include viruses, bacteria, fungus, and parasites. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately. Symptoms of encephalitis that might require emergency treatment include loss of consciousness, seizures, muscle weakness, or sudden severe dementia. Other symptoms include: sudden fever, headache, vomiting, heightened sensitivity to light, stiff neck and back, confusion and impaired judgment, drowsiness, weak muscles, a clumsy and unsteady gait, irritability. In more severe cases, people may have problems with speech or hearing, vision problems, and hallucinations. Symptoms of meningitis, which may appear suddenly, often include: high fever, severe and persistent headache, stiff neck, nausea, sensitivity to bright light, vomiting, and changes in behavior such as confusion, sleepiness, and difficulty waking up. In infants, symptoms of meningitis or encephalitis may include fever, vomiting, lethargy, body stiffness, unexplained irritability, and a full or bulging fontanel (the soft spot on the top of the head).

MalaCards based summary : Encephalitis is related to tick-borne encephalitis and herpes simplex encephalitis, and has symptoms including seizures, tremor and back pain. An important gene associated with Encephalitis is UNC93B1 (Unc-93 Homolog B1, TLR Signaling Regulator), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Azithromycin and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and t cells, and related phenotypes are no effect and Upregulation of RLR pathway after Sendai virus (SeV) infection

Disease Ontology : 12 A brain disease that is characterized as an acute inflammation of the brain with flu-like symptoms.

MedlinePlus : 43 Encephalitis is an inflammation of the brain. Usually the cause is a viral infection, but bacteria can also cause it. It can be mild or severe. Most cases are mild. You may have flu-like symptoms. With a mild case, you may just need rest, plenty of fluids, and a pain reliever. Severe cases need immediate treatment. Symptoms of severe cases include Severe headache Sudden fever Drowsiness Vomiting Confusion Seizures In babies, additional symptoms may include constant crying, poor feeding, body stiffness, and bulging in the soft spots of the skull. Severe cases may require a stay in the hospital. Treatments include oral and intravenous (IV) medicines to reduce inflammation and treat infection. Patients with breathing difficulties may need artificial respiration. Some people may need physical, speech, and occupational therapy once the illness is under control. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 75 Encephalitis is inflammation of the brain. Severity is variable. Symptoms may include headache, fever,... more...

Related Diseases for Encephalitis

Diseases in the Encephalitis family:

Viral Encephalitis Autoimmune Encephalitis
Chronic Encephalitis Infectious Encephalitis

Diseases related to Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1338)
# Related Disease Score Top Affiliating Genes
1 tick-borne encephalitis 34.6 TLR3 CXCL10 CD209 CCR5
2 herpes simplex encephalitis 34.5 UNC93B1 TRAF3 TLR3 TICAM1 IRF3
3 viral encephalitis 34.2 IL1B CXCL10 CCL5 CCL2
4 japanese encephalitis 33.8 TLR3 DDX58 CXCL10 CLEC4M CLEC4G CD209
5 west nile virus 32.6 TLR3 RSAD2 IRF3 DDX58 CLEC4M CD209
6 influenza 31.9 XPO1 TLR3 RSAD2 IRF3 DDX58 CCL5
7 measles 31.7 TLR3 DDX58 CD209
8 herpes simplex 31.7 UNC93B1 TRAF3 TLR3 TICAM1 IRF3 DDX58
9 dengue virus 31.5 RSAD2 RPSA DDX58 CD209
10 rabies 31.4 TLR3 IRF3 CXCL10 CCL5
11 malaria 31.2 IL1B CXCL9 CXCL10 CCL5 CCL2
12 mouth disease 31.1 TLR3 IRF3 IL1B
13 stomatitis 31.1 RSAD2 IL1B DDX58
14 viral meningitis 30.9 CXCL10 CCL5 CCL2
15 yellow fever 30.9 RSAD2 CCR5 CCL5 CCL2
16 neuritis 30.7 IL1B CXCL10 CCL5 CCL2
17 bacterial infectious disease 30.6 TLR3 IL1B CCL2
18 demyelinating disease 30.6 IL1B CXCL10 CCL5 CCL2
19 opsoclonus-myoclonus syndrome 30.5 CXCL9 CXCL10
20 trypanosomiasis 30.5 IL1B CCL5 CCL2
21 cytomegalovirus infection 30.4 IRF3 IL1B CCL5 CCL2
22 chikungunya 30.4 RSAD2 IL1B DDX58 CCL5 CCL2
23 lymphadenitis 30.3 IL1B CXCL9 CD209
24 central nervous system disease 30.3 IL1B GFAP CCR5 CCL2
25 pneumonia 30.2 IL1B CCL5 CCL2
26 sydenham chorea 30.0 CXCL9 CXCL10
27 proteasome-associated autoinflammatory syndrome 1 29.9 IL1B CXCL10 CCL5 CCL2
28 chagas disease 29.9 IL1B CCR5 CCL2
29 hepatitis c virus 29.8 RSAD2 IRF3 DDX58 CLEC4M CCR5
30 hepatitis c 29.8 TLR3 IRF3 DDX58 CXCL10 CLEC4M
31 mycobacterium tuberculosis 1 29.8 CXCL9 CXCL10 CD209
32 human immunodeficiency virus type 1 29.7 TLR3 IRF3 CXCL10 CLEC4M CD209 CCR5
33 severe acute respiratory syndrome 29.6 IRF3 CXCL10 CLEC4M CD209 CCL5 CCL2
34 pulmonary sarcoidosis 29.5 CCR5 CCL5 CCL2
35 multiple sclerosis 29.4 IL1B GFAP CXCL10 CCR5 CCL5 CCL2
36 viral infectious disease 29.4 TLR3 IRF3 IL1B DDX58 CXCL10 CD209
37 lung disease 29.3 IL1B CXCL10 CCL5 CCL2
38 la crosse encephalitis 12.8
39 eastern equine encephalitis 12.7
40 st. louis encephalitis 12.7
41 limbic encephalitis 12.6
42 western equine encephalitis 12.6
43 rasmussen encephalitis 12.6
44 murray valley encephalitis 12.6
45 granulomatous amebic encephalitis 12.6
46 west nile encephalitis 12.6
47 autoimmune encephalitis 12.6
48 meningitis and encephalitis 12.5
49 venezuelan equine encephalitis 12.5
50 powassan encephalitis 12.5

Graphical network of the top 20 diseases related to Encephalitis:

Diseases related to Encephalitis

Symptoms & Phenotypes for Encephalitis

UMLS symptoms related to Encephalitis:

seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Encephalitis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.26 CCL2 CCL5 CCR5 CD209 CLEC4G CLEC4M
2 Upregulation of RLR pathway after Sendai virus (SeV) infection GR00302-A 8.92 DDX58 IRF3 RPSA XPO1

MGI Mouse Phenotypes related to Encephalitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CCL5 CCR5 CLEC4G CLEC4M CXCL10 DDX58
2 homeostasis/metabolism MP:0005376 9.97 CCR5 CLEC4G CLEC4M CXCL10 DDX58 GFAP
3 immune system MP:0005387 9.83 CCL2 CCL5 CCR5 CLEC4G CLEC4M CXCL10
4 mortality/aging MP:0010768 9.4 CCR5 CLEC4M CXCL10 DDX58 GFAP IL1B

Drugs & Therapeutics for Encephalitis

Drugs for Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
leucovorin Approved Phase 4 58-05-9 143 6006
Ethanol Approved Phase 4 64-17-5 702
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
Racepinephrine Approved Phase 4 329-65-7 838
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
15 Hematinics Phase 4
16 Epoetin alfa Phase 4 113427-24-0
17 glucocorticoids Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Antibodies, Blocking Phase 4
20 Folic Acid Antagonists Phase 4
21 Vitamin B Complex Phase 4
22 Folate Phase 4
23 Vitamin B9 Phase 4
24 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
25 Disinfectants Phase 4
26 Neuroprotective Agents Phase 4
27 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
28 Antidepressive Agents Phase 4
29 Monoamine Oxidase Inhibitors Phase 4
30 Antiparkinson Agents Phase 4
31 Psychotropic Drugs Phase 4
32 Pharmaceutical Solutions Phase 4
33 Epinephryl borate Phase 4
34 Vasoconstrictor Agents Phase 4
35 Plasma Substitutes Phase 4
36 Polygeline Phase 4
37 Blood Substitutes Phase 4
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
Acyclovir Approved Phase 3 59277-89-3 2022
Famciclovir Approved, Investigational Phase 3 104227-87-4 3324
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
Loperamide Approved Phase 3 53179-11-6 3955
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
Carvedilol Approved, Investigational Phase 2, Phase 3 72956-09-3 2585
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
49 Immunosuppressive Agents Phase 2, Phase 3
50 DEET Phase 3

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Unknown status NCT03004209 Phase 4 Erythropoietin
2 Assessment of Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV Unknown status NCT01954810 Phase 4
3 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
4 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
5 An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population Completed NCT01158599 Phase 4
6 A Phase IV, Open-label, Multi-center Follow-up Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
7 Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine. Completed NCT01398540 Phase 4
8 A Phase IV, Randomized, Controlled, Single-Blind, Multi-Center Study in Children to Evaluate the Safety, Tolerability and Immunogenicity of Two TBE Vaccines Administered According to Two Different Schedules. Completed NCT00311441 Phase 4
9 A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
10 Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
11 Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
12 Open-label Phase Iv Study To Investigate The Seropersistence Of Tick-borne Encephalitis (Tbe) Virus Antibodies After The First Booster And The Response To A Second Booster Vaccination With Fsme-immun In Children, Adolescents And Young Adults (Follow-up To Study 700401) Completed NCT00894686 Phase 4
13 Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults Completed NCT01582698 Phase 4
14 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Completed NCT01656200 Phase 4
15 Post-licensure, Phase IV, Safety Study of IMOJEV® in Thailand Completed NCT01981967 Phase 4
16 A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
17 A Multi-center, Open, phase4 Study to Assess the Long-term Immunogenicity and Safety of Fourth Administration of BR JEV and to Investigate on Vaccine Interchangeability in Children Aged 6 Years Who Received 3 Doses With ENCEVAC or JEV-GCC Completed NCT02532569 Phase 4
18 A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Non-inferiority With Respect to an Earlier Product. Completed NCT01567865 Phase 4
19 Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine (IMOJEV) as a Booster Dose After a Primary Vaccination With CD.JEVAX in Thai Children Completed NCT02526550 Phase 4
20 A Phase IV, Uncontrolled, Open-Label, Multi-Center Study in Children and Adolescents: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New Pediatric TBE Vaccine (Free of Protein-Derived Stabilizer) in Study V48P4E1, Five Years After First Booster Immunization Completed NCT00452621 Phase 4
21 A Phase IV, Randomized, Open-Label, Multi-Center Study in Adults: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer) in Study V48P2E1, 5 Years After First Booster Immunization and Evaluation of Booster Kinetics in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer), 5 Years After First Booster Immunization Completed NCT00311493 Phase 4
22 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
23 A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization Completed NCT00387634 Phase 4
24 Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223) Completed NCT00503529 Phase 4
25 Neutralizing Antibody Titers 6 Years After the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection Completed NCT02039440 Phase 4
26 Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose Completed NCT02514746 Phase 4
27 Open-label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-borne Encephalitis Vaccine in Children and Adolescents Aged 3 - 18 Years Completed NCT00161967 Phase 4
28 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
29 Characterization of Humoral and Cellular Immunity of Low and High-responders After TBE Vaccination Completed NCT00804219 Phase 4
30 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463684 Phase 4
31 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
32 Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial. Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
33 Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun® Completed NCT02511587 Phase 4
34 Phase 4 Clinical Trial of Cervico-vaginal Immune Responses Following Three Right Deltoid or Right Thigh Intramuscular Immunisations With TicoVac (Tick Borne Encephalitis Virus [TBEV]) Vaccine in Adult Female Participants Completed NCT01710189 Phase 4 TicoVac
35 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
36 A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Manufactured in a New Good Manufacturing Practices Facility and Non-inferiority With Respect to an Earlier Product. Completed NCT01635816 Phase 4
37 Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study) Completed NCT01417949 Phase 4
38 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
39 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. Completed NCT00640159 Phase 4 Zelapar
40 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
41 Characterisation of Cellular and Humoral Immune Responses Following the First Booster Immunisation With the Inactivated, Purified Japanese Encephalitis Vaccine IXIARO® in Elderly Compared to Young Individuals. Recruiting NCT03971058 Phase 4
42 Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
43 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Recruiting NCT03519568 Phase 4
44 Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Active, not recruiting NCT03294135 Phase 4
45 Application of a TBE-Vaccine in Obese Persons Active, not recruiting NCT04017052 Phase 4 FSME-IMMUN Vaccine
46 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Enrolling by invitation NCT03296410 Phase 4
47 A Phase IV, Randomized, Open-label Study to Evaluate One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese Children Withdrawn NCT03192371 Phase 4
48 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
49 Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses? Unknown status NCT02318069 Phase 2, Phase 3
50 B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment. Unknown status NCT02229942 Phase 3 Rituximab;Placebo

Search NIH Clinical Center for Encephalitis

Cochrane evidence based reviews: encephalitis

Genetic Tests for Encephalitis

Genetic tests related to Encephalitis:

# Genetic test Affiliating Genes
1 Encephalitis 29

Anatomical Context for Encephalitis

MalaCards organs/tissues related to Encephalitis:

Brain, Testes, T Cells, Kidney, Bone, Lung, Temporal Lobe

Publications for Encephalitis

Articles related to Encephalitis:

(show top 50) (show all 30035)
# Title Authors PMID Year
Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis. 38 17
31189036 2019
Efficacy of acyclovir for herpes simplex encephalitis: A protocol for a systematic review of randomized controlled trial. 38 17
30985731 2019
Progressive multifocal leukoencephalopathy - epidemiology, immune response, clinical differences, treatment. 17
31181949 2019
Cytokines and chemokines in viral encephalitis: a clinicoradiological correlation. 9 38
20153811 2010
Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. 9 38
19200759 2009
Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. 9 38
18710325 2008
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. 9 38
18782012 2008
CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. 9 38
18678898 2008
Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. 9 38
18501510 2008
Increased expression of monocyte CD44v6 correlates with the deveopment of encephalitis in rhesus macaques infected with simian immunodeficiency virus. 9 38
18471064 2008
A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. 9 38
18179389 2008
Activated macrophages in HIV encephalitis and a macaque model show increased [3H](R)-PK11195 binding in a PI3-kinase-dependent manner. 9 38
17888571 2007
An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. 9 38
17240458 2007
Aquaporin 4 regulation during acute and long-term experimental Herpes simplex virus encephalitis. 9 38
17454447 2007
CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. 9 38
17107594 2006
Viral risk factor for seizures: pathobiology of dynorphin in herpes simplex viral (HSV-1) seizures in an animal model. 9 38
16843674 2006
CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection. 9 38
16753343 2006
Kappa opioid control of seizures produced by a virus in an animal model. 9 38
16399805 2006
Elevated concentration of the chemokine CCL3 (MIP-1alpha) in cerebrospinal fluid and serum of patients with tick borne encephalitis. 9 38
17357337 2006
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. 9 38
15961516 2005
[Serum and cerebrospinal concentrations of sICAM-1 sICAM-2, sICAM-3 in neuroborrellosis and tick borne encephalitis--preliminary report]. 9 38
16245421 2005
Neuroprotective and anti-human immunodeficiency virus activity of minocycline. 9 38
15855434 2005
Investigations on four host response factors whose expression is enhanced in X4 SHIV encephalitis. 9 38
15579283 2004
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. 9 38
15558055 2004
Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. 9 38
15111302 2004
Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. 9 38
14739339 2004
Cytokine production in brain of mice experimentally infected with dengue virus. 9 38
15106828 2004
Evaluation of antioxidant status in children with acute bacterial meningitis and encephalitis. 9 38
14585750 2003
Maedi-visna virus and caprine arthritis encephalitis virus genomes encode a Vpr-like but no Tat protein. 9 38
12915575 2003
Expression of the interferon-induced MxA protein in viral encephalitis. 9 38
12787324 2003
Lack of trans-activation function for Maedi Visna virus and Caprine arthritis encephalitis virus Tat proteins. 9 38
12667801 2003
Elevated peripheral benzodiazepine receptor expression in simian immunodeficiency virus encephalitis. 9 38
12587072 2003
The Tat protein of the caprine arthritis encephalitis virus interacts with the Notch2 EGF-like repeats and the epithelin/granulin precursor. 9 38
12931033 2003
Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. 9 38
12605891 2003
A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. 9 38
12491150 2002
Serum time course of two brain-specific proteins, alpha(1) brain globulin and neuron-specific enolase, in tick-born encephalitis and Lyme disease. 9 38
11983209 2002
Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. 9 38
11896158 2002
Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. 9 38
12162592 2002
Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. 9 38
11574916 2001
Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis. 9 38
11500085 2001
Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. 9 38
11282169 2001
[Diagnostic and prognostic significance of the antibodies to the myelin basic protein in acute neuroinfections in children]. 9 38
11209527 2001
Blood-brain barrier disruption in simian immunodeficiency virus encephalitis. 9 38
11054186 2000
Elevated cerebrospinal fluid level of ciliary neurotrophic factor in acute disseminated encephalomyelitis. 9 38
10980311 2000
Induction of cell-cycle regulators in simian immunodeficiency virus encephalitis. 9 38
10934153 2000
Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. 9 38
10640747 2000
Up-regulation of the hyaluronate receptor CD44 in canine distemper demyelinated plaques. 9 38
10672320 2000
Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. 9 38
10665489 2000
Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. 9 38
10595922 1999
Absence of brain-derived neurotrophic factor and trkB receptor immunoreactivity in glia of Alzheimer's disease. 9 38
10502038 1999

Variations for Encephalitis

ClinVar genetic disease variations for Encephalitis:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ABCD1 NM_000033.4(ABCD1): c.1866-1G> C single nucleotide variant Likely pathogenic rs1557055311 X:153008674-153008674 X:153743220-153743220

Expression for Encephalitis

Search GEO for disease gene expression data for Encephalitis.

Pathways for Encephalitis

Pathways related to Encephalitis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.32 TLR3 TICAM1 IRF3 DDX58
Show member pathways
12.22 TRAF3 IL1B CXCL10 CCL2
Show member pathways
Show member pathways
Show member pathways
Show member pathways
15 11.92 IL1B GFAP CXCL10 CCL2
16 11.85 TRAF3 IL1B CXCL10 CCL5 CCL2
18 11.83 TRAF3 TICAM1 IL1B DDX58
19 11.76 IL1B CCL5 CCL2
20 11.66 TICAM1 IRF3 IL1B
21 11.62 IL1B CXCL9 CXCL10 CCL5 CCL2
22 11.55 IL1B CCL5 CCL2
23 11.3 IL1B CXCL9 CXCL10
24 11.12 IL1B CXCL9 CXCL10 CCL5 CCL2
25 11.04 IL1B CXCL10 CCR5 CCL5 CCL2
27 10.84 IL1B CCL2

GO Terms for Encephalitis

Cellular components related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 host cell GO:0043657 8.8 XPO1 CLEC4M CD209

Biological processes related to Encephalitis according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 TLR3 TICAM1 IRF3 IL1B
2 response to lipopolysaccharide GO:0032496 9.97 TICAM1 IRF3 IL1B CXCL10
3 inflammatory response GO:0006954 9.97 TLR3 TICAM1 IL1B CXCL9 CXCL10 CCR5
4 innate immune response GO:0045087 9.97 UNC93B1 TRAF3 TLR3 TICAM1 RSAD2 IRF3
5 defense response GO:0006952 9.96 TLR3 CXCL9 CXCL10 CCR5
6 chemotaxis GO:0006935 9.96 CXCL9 CXCL10 CCR5 CCL5 CCL2
7 response to bacterium GO:0009617 9.92 IRF3 CXCL9 CXCL10 CCL2
8 response to virus GO:0009615 9.91 TLR3 RSAD2 DDX58 CXCL10 CCL5
9 viral entry into host cell GO:0046718 9.89 RPSA CLEC4M CLEC4G CD209
10 cellular response to interferon-gamma GO:0071346 9.88 TLR3 CCL5 CCL2
11 cell chemotaxis GO:0060326 9.88 CXCL10 CCR5 CCL5 CCL2
12 neutrophil chemotaxis GO:0030593 9.88 IL1B CXCL9 CXCL10 CCL5 CCL2
13 cellular response to organic cyclic compound GO:0071407 9.87 IL1B CCL5 CCL2
14 positive regulation of interleukin-6 production GO:0032755 9.87 TLR3 TICAM1 IL1B DDX58
15 positive regulation of T cell proliferation GO:0042102 9.86 IL1B CD209 CCL5
16 toll-like receptor signaling pathway GO:0002224 9.83 UNC93B1 TRAF3 TLR3
17 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL9 CXCL10 CCR5 CCL5 CCL2
18 protein kinase B signaling GO:0043491 9.82 IL1B CCL5 CCL2
19 positive regulation of type I interferon production GO:0032481 9.82 TLR3 TICAM1 IRF3
20 response to exogenous dsRNA GO:0043330 9.8 TLR3 TICAM1 IRF3 DDX58
21 positive regulation of interleukin-8 production GO:0032757 9.79 TLR3 IL1B DDX58
22 leukocyte cell-cell adhesion GO:0007159 9.79 CLEC4M CD209 CCL5
23 positive regulation of interferon-beta production GO:0032728 9.78 TLR3 IRF3 DDX58
24 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.76 TRAF3 TLR3 TICAM1 IRF3
25 viral genome replication GO:0019079 9.75 CLEC4M CD209 CCL2
26 necroptotic process GO:0070266 9.72 TLR3 TICAM1
27 positive regulation of monocyte chemotaxis GO:0090026 9.72 CXCL10 CCL5
28 positive regulation of glial cell proliferation GO:0060252 9.72 IL1B GFAP
29 toll-like receptor 3 signaling pathway GO:0034138 9.72 UNC93B1 TLR3 TICAM1
30 dendritic cell chemotaxis GO:0002407 9.71 CCR5 CCL5
31 positive regulation of T cell migration GO:2000406 9.71 CXCL10 CCL5
32 cellular response to exogenous dsRNA GO:0071360 9.71 TLR3 DDX58
33 positive regulation of interferon-alpha production GO:0032727 9.71 IRF3 DDX58
34 intracellular transport of virus GO:0075733 9.71 XPO1 CLEC4M CD209
35 macrophage chemotaxis GO:0048246 9.7 CCL5 CCL2
36 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.7 IL1B DDX58
37 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.7 TLR3 TICAM1
38 positive regulation of chemokine biosynthetic process GO:0045080 9.7 TLR3 TICAM1 IL1B
39 cellular response to lipopolysaccharide GO:0071222 9.7 TICAM1 IRF3 IL1B CXCL9 CXCL10 CCR5
40 positive regulation of interferon-beta biosynthetic process GO:0045359 9.69 TLR3 TICAM1
41 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.68 TLR3 TICAM1
42 modulation by virus of host morphology or physiology GO:0019048 9.68 CLEC4M CD209
43 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.68 TICAM1 DDX58
44 negative regulation of macrophage apoptotic process GO:2000110 9.68 CCR5 CCL5
45 cell-cell recognition GO:0009988 9.67 CLEC4M CD209
46 virion attachment to host cell GO:0019062 9.66 CLEC4M CD209
47 detection of virus GO:0009597 9.66 TLR3 DDX58
48 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 TICAM1 IRF3 IL1B CCL5 CCL2
49 peptide antigen transport GO:0046968 9.64 CLEC4M CD209
50 viral process GO:0016032 9.61 XPO1 RSAD2 RPSA IRF3 DDX58 CLEC4M

Molecular functions related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 IL1B CXCL9 CXCL10 CCL5 CCL2
2 virion binding GO:0046790 9.37 CLEC4M CD209
3 CXCR3 chemokine receptor binding GO:0048248 9.26 CXCL9 CXCL10
4 chemokine activity GO:0008009 9.26 CXCL9 CXCL10 CCL5 CCL2
5 virus receptor activity GO:0001618 9.02 RPSA CLEC4M CLEC4G CD209 CCR5
6 protein binding GO:0005515 10.25 XPO1 TRAF3 TLR3 TICAM1 RSAD2 RPSA

Sources for Encephalitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....